[HTML][HTML] Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
SS Ramalingam, S Kummar… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Vorinostat is the first US Food and Drug Administration–approved histone
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
SS Ramalingam, S Kummar… - Journal of Clinical …, 2010 - ascopubs.org
Purpose Vorinostat is the first US Food and Drug Administration–approved histone
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group study
SS Ramalingam, S Kummar… - Journal of Clinical …, 2010 - ohsu.elsevierpure.com
Purpose: Vorinostat is the first US Food and Drug Administration-approved histone
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
[PDF][PDF] Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group …
SS Ramalingam, S Kummar, J Sarantopoulos… - Clinical …, 2010 - researchgate.net
Purpose Vorinostat is the first US Food and Drug Administration–approved histone
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
SS Ramalingam, S Kummar… - Journal of Clinical …, 2010 - europepmc.org
Purpose Vorinostat is the first US Food and Drug Administration-approved histone
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
SS Ramalingam, S Kummar, J Sarantopoulos… - Journal of Clinical …, 2010 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Purpose</jats: title>< jats: p> Vorinostat is the first US Food and
Drug Administration–approved histone deacetylase inhibitor and is indicated for the …
Drug Administration–approved histone deacetylase inhibitor and is indicated for the …
[引用][C] Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group …
SS RAMALINGAM, S KUMMAR, SP IVY… - Journal of clinical …, 2010 - pascal-francis.inist.fr
Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A
National Cancer Institute Organ Dysfunction Working Group Study CNRS Inist Pascal-Francis …
National Cancer Institute Organ Dysfunction Working Group Study CNRS Inist Pascal-Francis …
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: A National Cancer Institute Organ Dysfunction Working Group study
SS Ramalingam, S Kummar… - Journal of Clinical …, 2010 - scholars.uthscsa.edu
Purpose: Vorinostat is the first US Food and Drug Administration-approved histone
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
[PDF][PDF] Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group …
SS Ramalingam, S Kummar, J Sarantopoulos… - Clinical Oncology, 2010 - accrf.org
Purpose Vorinostat is the first US Food and Drug Administration–approved histone
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
SS Ramalingam, S Kummar… - Journal of clinical …, 2010 - pubmed.ncbi.nlm.nih.gov
Purpose Vorinostat is the first US Food and Drug Administration-approved histone
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …
deacetylase inhibitor and is indicated for the treatment of refractory cutaneous T-cell …